Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.
作者信息
Kramer L D
机构信息
Lynn D. Kramer, MD, Eisai Inc. Woodcliff Lake New Jersey, 07677, USA, Email:
出版信息
J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.
PMID:32463064
Abstract
摘要
相似文献
1
Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.社论：行业视角：抗淀粉样蛋白试验的未来
J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.
2
Editorial: Next-Generation Alzheimer's Therapeutics: Leveraging Deep Biology.社论：下一代阿尔茨海默病治疗方法：利用深度生物学
J Prev Alzheimers Dis. 2020;7(3):138-139. doi: 10.14283/jpad.2020.30.
3
Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.评论：欧盟/美国特别工作组关于抗淀粉样蛋白试验的未来：各显神通。
J Prev Alzheimers Dis. 2020;7(3):199-200. doi: 10.14283/jpad.2020.29.
4
The Future of Anti-Amyloid Trials.抗淀粉样蛋白治疗临床试验的未来。
J Prev Alzheimers Dis. 2020;7(3):146-151. doi: 10.14283/jpad.2020.24.
5
Alzheimer antibody drugs show questionable potential.阿尔茨海默病抗体药物显示出可疑的潜力。
Nat Rev Drug Discov. 2015 Sep;14(9):591-2. doi: 10.1038/nrd4709.
6
Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials.为何淀粉样蛋白仍是阿尔茨海默病临床试验的靶点。
J Am Geriatr Soc. 2019 Apr;67(4):845-847. doi: 10.1111/jgs.15829. Epub 2019 Mar 9.
7
Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.治疗阿尔茨海默病药物的挫折与希望：随着制药公司纷纷退出阿尔茨海默病药物研发，学术界和生物技术公司正在测试新的方法。
EMBO Rep. 2018 Sep;19(9). doi: 10.15252/embr.201846714. Epub 2018 Aug 27.
8
Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.阿尔茨海默病的淀粉样蛋白之外：未来治疗干预的策略。
BMJ. 2020 Oct 9;371:m3684. doi: 10.1136/bmj.m3684.
9
Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease.重大临床试验未能证实阿尔茨海默病的淀粉样蛋白假说。
J Am Geriatr Soc. 2019 Apr;67(4):841-844. doi: 10.1111/jgs.15830. Epub 2019 Mar 9.
10
Editorial: A Is for Amyloid.社论：A代表淀粉样蛋白。
J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.
引用本文的文献
1
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.抗淀粉样蛋白-β单克隆抗体对阿尔茨海默病患者临床和生物标志物结局及不良事件风险的影响：一项系统评价和 III 期 RCT 的荟萃分析
Ageing Res Rev. 2021 Jul;68:101339. doi: 10.1016/j.arr.2021.101339. Epub 2021 Apr 5.
Zotero 插件